Advanced gastric cancer with liver metastases successfully treated with S-1

International Journal of Clinical Oncology

Volumn 7, Issue 5, 2002, Pages 326-329

  Watanabe, Shin ^a   Tanaka, Takashi ^a   Takeuchi, Tadayuki ^a   Takabayashi, Hiroshi ^a   Hirayama, Yoji ^a  

^a Icho Hospital   (Japan)

Author keywords

Gastric cancer; Liver metastases; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR;

AGED; ANEMIA; ANOREXIA; ARTICLE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LIVER METASTASIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SIDE EFFECT; STOMACH ADENOCARCINOMA; STOMACH CANCER;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DRUG COMBINATIONS; FEMALE; HUMANS; LIVER NEOPLASMS; OXONIC ACID; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR;

EID: 0036808619     PISSN: 13419625     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101470200049     Document Type: Article

References (10)

1. Pyrhonen S, Kuitunen T, Nyandoto P, et al. (1995) Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591
2. Chung Y, Yamashita Y, Nakata B, et al. (1995) Combination therapy of 5-FU and low dose CDDP for advanced and recurrent gastric cancer. Jpn J Cancer Chemother 22:149-151
3. Boku N, Ohtsu A, Shimada Y, et al. (1999) Phase Il study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17:319-323
4. Sakata Y, Ohtsu A, Horikoshi N, et al. (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34:1715-1720.
5. Koizumi W, Kurihara M, Nakano S, et al. (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology 58:191-197
6. Japanese Gastric Cancer Association (2001) Japanese classification of gastric carcinoma, 2nd English ed. Response assessment of chemotherapy and radiotherapy for gastric carcinoma: Clinical criteria. Gastric Cancer 4:1-8
7. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004-4009
8. Shirasaka T, Shimarnoto Y, Ohshimo H, et al. (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557
9. Diasio RB (1999) Clinical implications of dihydropyrimidine dehydrogenase inhibition. Oncology 13(Suppl 3):17-21
10. Hirata K, Horikoshi N, Aiba K, et al. (2000) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5:2000-2005